We are live on ! Find out more

Bionano Genomics

BNGO

Market cap $18.4M

1.56 USD

+0.23

17.29%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

1.65

+0.09

5.77%

1 day

17.29%

5 days

31.09%

1 month

31.09%

3 months

34.48%

6 months

40.54%

Year to date

-1.89%

1 year

-43.68%

5 years

-99.95%

10 years

-99.96%

About: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

Employees: 97

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia

Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasms Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML, and therapy-related myeloid neoplasms

Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia

Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors (MACs), has issued a proposed Local Coverage Determination (LCD) for Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms.

Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping

New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders, and hematologic malignancies at University of Rochester Medicine New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders, and hematologic malignancies at University of Rochester Medicine

Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping

Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026.

Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2026 and to highlight recent corporate progress.

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

Bionano Announces Hiring of Chief Scientific Officer

SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer (CSO), effective July 20, 2026. In this role, Dr. Hastie will lead the company's global scientific strategy, innovation roadmap, and research initiatives, advancing Bionano's mission to expand the research application of its genome analysis technologies and to develop a clinical applications strategy.

Bionano Announces Hiring of Chief Scientific Officer

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared to the conference in 2025, consistent with expanding global adoption of OGM. Key highlights from studies of OGM presented at ESHG 2026: 35 studies featured OGM — a 67% increase over the 21 studies reported at ESHG 2025.

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that demonstrate the utility of optical genome mapping (OGM) for the detection and characterization of structural variants (SVs) in studies of reproductive health and prenatal genetic disorders. Reproductive disorders including infertility and recurrent pregnancy loss are highly prevalent and very often carry a genetic component.

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

Zacks Investment Research

Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?

Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?

See News Rankings

Price charts implemented using Lightweight Charts™